Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4642 + AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer
NCT06587061Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HRS-4642 in pancreatic cancer (PC), sponsored by Ruijin Hospital. Primary endpoints: Adverse events at 30 days and Objective Response Rate at 6 months. Started Dec 2024; status: recruiting.
02
Drugs
HRS-4642
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06587061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587061.